Trial · NCT03937843
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
NCT03937843, Phase 2, Active not recruiting, Swiss Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. Trials, record NCT03937843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03937843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
- NCT number
- NCT03937843
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 135 participants, actual
- Lead sponsor
- Swiss Cancer Institute
- Conditions
- Seminoma, Testicular Cancer
- Interventions
- Carboplatin, Cisplatin, Etoposide
- First posted
- 2019-05-06
- Last updated
- 2026-01-20
- Other registries' IDs
- eudract:2019-000514-11
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) at 3 years | From the date of registration until the date of progressive disease, relapse or death, whichever occurs first, assessed up to 3 years after registration | PFS is defined as the time from registration until one of the following events occurs: * Progressive disease or relapse, defined as progression according to the modified trial-specific version of RECIST 1.1 or a rising level of the tumor marker beta-hCG (beta human chorionic gonadotropin) over the ULN (Upper limit of normal), confirmed by a second measurement. Presence of non-seminoma germ cell tumor has to be excluded in the latter case * Death from any cause. |
| Secondary | Response rate (RR) | at 3 months and 3 years after registration | The response is categorized according to the modified trial-specific version of RECIST 1.1 measurability criteria as: complete remission (CR), partial remission (PR), stable disease (SD), progressive disease (PD). The response rate is defined as proportion of patients with CR or PR on imaging assessment and without rising beta-hCG. Patients with CR, PR and SD on imaging assessment, but with confirmed rising beta-hCG will not be counted as responders, if the presence on non-seminoma germ cell tumor was excluded. Response rate will be evaluated at 3 months and 3 years after registration. |
| Secondary | Progression free survival (PFS) | From the date of registration until the date of progressive disease, relapse or death, whichever occurs first, assessed up to 20 years after registration | |
| Secondary | Time to progression (TTP) | From the date of registration until the date of progressive disease, relapse or death due to progression, whichever occurs first, assessed up to 20 years after registration | TTP is defined as the time from registration until documented PD or relapse according to the modified trial-specific version of RECIST 1.1 or death due to progression, whichever occurs first. Patients without an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of the last tumor assessment showing non-progression before the start of a new therapy, if any. |
| Secondary | Overall Survival (OS) | From the date of registration until the date of death from any cause, assessed up to 20 years after registration | OS is defined as the time from registration to the date of death from any cause. Patients who did not experience an event will be censored at the last known time they were known to be alive. |
| Secondary | Seminoma-specific survival | From the date of registration until the date of death due to seminoma, assessed up to 20 years after registration | Seminoma-specific survival is defined as the time from registration to the date of death due to seminoma. Patients who did not experience an event will be censored at the last known time they were known to be alive. |
| Secondary | Time to distant metastasis | From the date of registration until the date of first occurrence of distant metastasis, assessed up to 20 years after registration | Time to distant metastasis is defined as the time from registration until first occurrence of distant metastasis. Patients not experiencing an event will be censored at the date of the last available assessment. |
| Secondary | Time to next treatment | From the date of registration until the date of start of any new anticancer therapy for progressive seminoma, assessed up to 20 years after registration | Time to next treatment is defined as the time from registration to the start of any new anticancer therapy for progressive seminoma. Patients not receiving any new treatment are censored at the last date they were known to be alive. |
| Secondary | Localization of progression | at the date of the first occurrence of progressive disease, assessed from registration up to 20 years after registration | The localization of progression is defined as the first localization where progressive disease is detected. It is divided into the following sites: * Initially involved lymph node area * Non-initially involved paraaortic \& pelvic lymph node area * Supradiaphragmatic lymph node area * Organ involvement (lung, liver, bones, etc.) * Multiple sites simultaneously |
| Secondary | Method of detection of progression | at the date of the first occurrence of progressive disease, assessed from registration up to 20 years after registration | The method of detection of progression is defined as the first method used to detect the first progression event and comprises the following categories: * Physical examination (inspection, palpation, etc.) * Rising beta-hCG tumor marker * CT imaging * Ultrasound imaging * X-ray imaging * Other imaging (e. g. MRI, PET-CT) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03937843
GET https://conductscience.org/api/trials/v1/NCT03937843/registered